Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, skin disease. Adalimumab is the only approved drug for the treatment of hidradenitis suppurativa (HS), but it only partially controls the symptoms.
Caposiena Caro, R.d., Cannizzaro, M.v., Tartaglia, C., Bianchi, L. (2019). Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. CLINICAL AND EXPERIMENTAL DERMATOLOGY [10.1111/ced.14127].
Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab
Bianchi, L
2019-10-20
Abstract
Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, skin disease. Adalimumab is the only approved drug for the treatment of hidradenitis suppurativa (HS), but it only partially controls the symptoms.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clinical response rate and flares of hidradenitis suppurativa in the treatment with.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
6.49 MB
Formato
Adobe PDF
|
6.49 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
